Skip to main content

Table 1 Baseline patient and disease characteristics

From: Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

Characteristic

Ruxolitinib (n = 68)

BAT (n = 192)

p

Demographics

 Mean age (95% CI), years

66.8 (65.1 to 68.5)

59.1 (57.7 to 61.3)

< 0.001

 Male sex, %

57

48

0.205

Clinical parameters

IPSS risk status, %

  

0.001

 High risk

57

15

 

 Intermediate-2

31

16

 

 Intermediate-1

12

39

 

 Low risk

0

30

 

Mean spleen size (95% CI), cma

19.6 (18.4 to 21.6)

3.6 (3.0 to 4.2)

0.001

Mean hemoglobin (95% CI), g/dL

10.8 (10.3 to 11.3)

12.1 (11.7 to 12.5)

0.001

Mean platelet count (95% CI), × 109/L

401.4 (341.0 to 462.9)

521.1 (464.6 to 577.5)

0.015

Mean WBC count (95% CI), ×109/L

17.7 (14.2 to 21.3)

13.4 (11.6 to 15.3)

0.021

Mean peripheral blasts (95% CI), %

0.8 (0.5 to 1.1)

0.5 (0.3 to 0.7)

0.097

WHO grade of BM fibrosisb, %

 Grade 1

22

37

0.098

 Grade 2

53

52

 

 Grade 3

25

11

 
  1. BAT best available therapy, CI confidence interval, IPSS International Prognostic Scoring System, WBC white blood cell, BM bone marrow
  2. aPalpable spleen length below costal margin
  3. bBAT patients with ≥ 60 months follow-up during study